A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

NCT07179640 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypophosphatasia (HPP)

Interventions

DRUG: ALE1
DRUG: Placebo

Sponsor

Alesta Therapeutics